PCSA Processa Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1533743 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,393.5%
TTM EPS YoY34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-203.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1.0%
Debt / equity—
Current ratio97.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.07x
Accruals ratio-189.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $7.81M | $7.27M |
| SG&A expense | $6.18M | $4.78M |
| Operating income | -$13.99M | -$12.05M |
| Pretax income | -$13.56M | -$11.85M |
| Net income | -$13.56M | -$11.85M |
| EBITDA | -$13.99M | -$12.05M |
| EPS (basic) | -10.36 | -96.78 |
| EPS (diluted) | -10.36 | -96.78 |
| Weighted avg. shares (diluted) | 1.31M | 122,438 |
| Balance sheet | ||
| Cash & equivalents | $5.54M | $1.19M |
| Current assets | $5.67M | $1.88M |
| PP&E, net | $4,000 | $5,016 |
| Total assets | $7.81M | $3.23M |
| Current liabilities | $2.24M | $1.53M |
| Total liabilities | $2.24M | $1.53M |
| Shareholders' equity | $5.58M | $1.70M |
| Shares outstanding | 2.57M | 148,108 |
| Cash flow statement | ||
| Operating cash flow | -$11.39M | -$11.25M |
| Capital expenditure | — | $3,244 |
| Free cash flow | — | -$11.25M |
| Investing cash flow | -$850,000 | -$3,244 |
| Financing cash flow | $16.58M | $7.73M |
| Depreciation & amortization | $1,204 | $782 |
| Stock-based compensation | $857,550 | $629,514 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.